AFM
TMBR

Anson Funds Management’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Anson Funds Management’s Portfolio TMBR Stock Details TMBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-14
Closed -$114K – 104
2016
Q3 		$114K Buy
+14
New +$148K 0.02% 56

Other funds holding TMBR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Anson Funds Management's TMBR Position: Q4 2016 in Review

Anson Funds Management sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q4 2016, closing a stake of 14 shares — an estimated $114K sold.

Anson Funds Management first reported a position in TMBR in Q3 2016 and held it in 1 quarter. The position peaked at $114K in Q3 2016. 14 funds tracked by Wall St. Rank hold TMBR as of Q4 2016.

  • Anson Funds Management reported no remaining Timber Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Anson Funds Management sold 14 Timber Pharmaceuticals, Inc. shares in Q4 2016, an estimated $114K.
  • Anson Funds Management first reported a position in Timber Pharmaceuticals, Inc. in Q3 2016 and held it in 1 quarter.
  • Anson Funds Management's Timber Pharmaceuticals, Inc. position peaked at $114K in Q3 2016.
  • 14 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q4 2016.

Based on Anson Funds Management's 13F filing for Q4 2016, filed 14 Feb 2017.